

July 31, 2019

Department of Corporate Services Bombay Stock Exchange Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Mr. Hari K Asst. Vice President - Operations National Stock Exchange of India Ltd Exchange Plaza, Bandra – Kurla Complex Bandra (East), Mumbai – 400 051

Ref: BSE Scrip Code -506690: NSE Symbol – UNICHEMLAB

Dear Sir,

<u>Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.</u>

The United States Food and Drug Administration (USFDA) conducted inspection at the Company's Goa formulation facility between July 22 to July 31, 2019.

The inspection was a routine GMP surveillance and Post Approval Inspection for our ANDAs submitted from this facility. At the end of Inspection, the facility received 4 observations, with no repeat observations and are mostly procedural in nature.

Unichem will provide the responses and corrective action plan within next 15 working days to address the USFDA observations.

Please take the above on record.

Thanks and Regards

Sandip Ghume

Deputy CFO

ABORA MUMBAI 400 100

